GlassScriptPhysician profile
Ethan Weshinskey
NPI 1457722910
$3,367.58
in general payments reported to CMS, 2019-2025
33 companies · $1,127 in 2025
The $1,127 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $454 · 2023: $859 · 2024: $659 · 2025: $1,127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $659.03 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $326.70 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $314.15 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $242.61 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $233.39 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $168.62 | 2021-2025 | |
| Indivior INC. | $167.84 | 2023-2025 | Sublocade, Perseris |
| Glaxosmithkline, LLC. | $149.02 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.75 | 2021-2023 | Xifaxan |
| Braeburn INC. | $126.41 | 2024-2025 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.66 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Otsuka America Pharmaceutical, INC. | $68.10 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $65.41 | 2024-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.62 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $59.98 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $59.37 | 2022-2025 | Trintellix |
| Abbott Laboratories | $51.52 | 2025 | Freestyle Libre |
| Amgen INC. | $51.18 | 2024-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $48.70 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $45.10 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $38.78 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $35.17 | 2022-2023 | Uzedy |
| Viiv Healthcare Company | $24.70 | 2025 | Apretude |
| Neurocrine Biosciences, INC. | $23.64 | 2025 | |
| Lundbeck LLC | $23.14 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $19.94 | 2024 | Spravato |
| Philips North America LLC | $17.15 | 2023 | |
| Sumitomo Pharma America, INC. | $16.46 | 2024 | Gemtesa |
| Seqirus USA INC | $16.28 | 2024 | Fluad, Flucelvax |
| Merck Sharp & Dohme LLC | $16.14 | 2024 | Vaxelis, Gardasil, Vaqta |
| Phathom Pharmaceuticals, INC. | $14.22 | 2024 | Voquezna |
| Almatica Pharma LLC | $13.85 | 2021 | |
| Axsome Therapeutics, INC. | $10.95 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ethan Weshinskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.